Antiangiogenic strategies in breast cancer management

作者：Giovannini Monica^*; Aldrighetti Daniela; Zucchinelli Patrizia; Belli Carmen; Villa Eugenio

来源：Critical Reviews in Oncology/Hematology, 2010, 76(1): 13-35.

DOI：10.1016/j.critrevonc.2009.12.004

• Breast cancer angiogenesis
• Antiangiogenic agents
• Monoclonal antibodies
• Tyrosin kinase inhibitors
• Metronomic chemotherapy
• Bisphosphonates
• Hormonal therapy
• COX-2 inhibitors

Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others.
In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.

• 出版日期2010-10